Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 1;184(7):1661-1670.
doi: 10.1016/j.cell.2021.02.055.

The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment

Henry Rodriguez  1 , Jean Claude Zenklusen  2 , Louis M Staudt  2 , James H Doroshow  3 , Douglas R Lowy  4
Affiliations
Review

The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment

Henry Rodriguez et al. Cell. .

Abstract

When it comes to precision oncology, proteogenomics may provide better prospects to the clinical characterization of tumors, help make a more accurate diagnosis of cancer, and improve treatment for patients with cancer. This perspective describes the significant contributions of The Cancer Genome Atlas and the Clinical Proteomic Tumor Analysis Consortium to precision oncology and makes the case that proteogenomics needs to be fully integrated into clinical trials and patient care in order for precision oncology to deliver the right cancer treatment to the right patient at the right dose and at the right time.

Keywords: cancer diagnosis; cancer treatment; clinical trial; collaboration; data sharing; genomics; molecular medicine; open access; precision medicine; precision oncology; proteogenomics; proteomics; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

Figure 1:
Figure 1:
In this figurative piece, the role of proteogenomics in precision oncology is illustrated by a cancer patient looking out into the horizon. His horizon is framed by DNA and RNA hills (genomics) and protein clouds (proteomics) which together represent the keys to overcoming scientific mountains. The strong ray of sunlight embodies the current contributions of genomics to oncology, lighting the path to the next step in the journey, multi-omics molecular characterization of patient tumors. The patient looks forward to a brighter horizon, one where genomic and proteomic molecular diagnoses are combined into clinical trials and patient care, one where patients and families are gifted with hope.
See this image and copyright information in PMC

References

    1. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, et al. (2009). Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27, 633–641. - PMC - PubMed
    1. Bedard PL, Hansen AR, Ratain MJ, and Siu LL (2013). Tumour heterogeneity in the clinic. Nature 501, 355–364. - PMC - PubMed
    1. Blum A, Wang P, and Zenklusen JC (2018). SnapShot: TCGA-Analyzed Tumors. Cell 173, 530. - PubMed
    1. Borner K, Contractor N, Falk-Krzesinski HJ, Fiore SM, Hall KL, Keyton J, Spring B, Stokols D, Trochim W, and Uzzi B. (2010). A multi-level systems perspective for the science of team science. Sci Transl Med 2, 49cm24. - PMC - PubMed
    1. Budnik B, Levy E, Harmange G, and Slavov N. (2018). SCoPE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation. Genome Biology 19, 161. - PMC - PubMed